162 related articles for article (PubMed ID: 37975819)
21. T-Track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients.
Gliga S; Korth J; Krawczyk A; Wilde B; Horn PA; Witzke O; Lindemann M; Fiedler M
J Clin Virol; 2018 Aug; 105():91-96. PubMed ID: 29936407
[TBL] [Abstract][Full Text] [Related]
22. An optimized IFN-γ ELISpot assay for the sensitive and standardized monitoring of CMV protein-reactive effector cells of cell-mediated immunity.
Barabas S; Spindler T; Kiener R; Tonar C; Lugner T; Batzilla J; Bendfeldt H; Rascle A; Asbach B; Wagner R; Deml L
BMC Immunol; 2017 Mar; 18(1):14. PubMed ID: 28270111
[TBL] [Abstract][Full Text] [Related]
23. Cytomegalovirus-specific cytokine-induced killer cells: concurrent targeting of leukemia and cytomegalovirus.
Pfirrmann V; Oelsner S; Rettinger E; Huenecke S; Bonig H; Merker M; Wels WS; Cinatl J; Schubert R; Klingebiel T; Bader P
Cytotherapy; 2015 Aug; 17(8):1139-51. PubMed ID: 26072027
[TBL] [Abstract][Full Text] [Related]
24. Optimization of interferon gamma ELISPOT assay to detect human cytomegalovirus specific T-cell responses in solid organ transplants.
Abate D; Saldan A; Forner G; Tinto D; Bianchin A; Palù G
J Virol Methods; 2014 Feb; 196():157-62. PubMed ID: 24216234
[TBL] [Abstract][Full Text] [Related]
25. [Comparison of single infusion of anti-BCMA versus combined infusion of anti-CD19 chimeric antigen receptor T cells for immune reconstruction in relapsed/refractory multiple myeloma].
Ge J; Zhao TT; Wan CY; Xia JY; Guo SY; Yu MX; Chen J; Wang Y; Xu KL; Li ZY
Zhonghua Xue Ye Xue Za Zhi; 2021 Sep; 42(9):733-738. PubMed ID: 34753227
[No Abstract] [Full Text] [Related]
26. Validation of T-Track® CMV to assess the functionality of cytomegalovirus-reactive cell-mediated immunity in hemodialysis patients.
Banas B; Böger CA; Lückhoff G; Krüger B; Barabas S; Batzilla J; Schemmerer M; Köstler J; Bendfeldt H; Rascle A; Wagner R; Deml L; Leicht J; Krämer BK
BMC Immunol; 2017 Mar; 18(1):15. PubMed ID: 28270092
[TBL] [Abstract][Full Text] [Related]
27. Cytomegalovirus immune reconstitution occurs in recipients of allogeneic hematopoietic cell transplants irrespective of detectable cytomegalovirus infection.
Gallez-Hawkins G; Thao L; Lacey SF; Martinez J; Li X; Franck AE; Lomeli NA; Longmate J; Diamond DJ; Spielberger R; Forman SJ; Zaia JA
Biol Blood Marrow Transplant; 2005 Nov; 11(11):890-902. PubMed ID: 16275592
[TBL] [Abstract][Full Text] [Related]
28. Cytomegalovirus Retinitis and Retinal Detachment following Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory Multiple Myeloma.
Zu C; Xu Y; Wang Y; Zhang M; Zhao H; Fang X; Huang H; Hu Y
Curr Oncol; 2022 Jan; 29(2):490-496. PubMed ID: 35200544
[TBL] [Abstract][Full Text] [Related]
29. Cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in seropositive kidney transplant recipients.
Lee H; Park KH; Ryu JH; Choi AR; Yu JH; Lim J; Han K; Kim SI; Yang CW; Chung BH; Oh EJ
PLoS One; 2017; 12(12):e0189488. PubMed ID: 29232714
[TBL] [Abstract][Full Text] [Related]
30. Human Herpesvirus-6 Reactivation and Disease Are Infrequent in Chimeric Antigen Receptor T-cell Therapy Recipients.
Kampouri E; Krantz EM; Xie H; Ibrahimi SS; Kiem ES; Sekhon MK; Liang EC; Cowan AJ; Portuguese AJ; Green DJ; Albittar A; Huang JJ; Gauthier J; Pérez-Osorio AC; Jerome KR; Zerr D; Boeckh MJ; Hill JA
Blood; 2024 Apr; ():. PubMed ID: 38635788
[TBL] [Abstract][Full Text] [Related]
31. Expansion of cytomegalovirus pp65 and IE-1 specific cytotoxic T lymphocytes for cytomegalovirus-specific immunotherapy following allogeneic stem cell transplantation.
Bao L; Dunham K; Stamer M; Mulieri KM; Lucas KG
Biol Blood Marrow Transplant; 2008 Oct; 14(10):1156-1162. PubMed ID: 18804046
[TBL] [Abstract][Full Text] [Related]
32. CMV-Specific Cell-Mediated Immunity Predicts a High Level of CMV Replication After Prophylaxis Withdrawal in Lung Transplant Recipients.
Donadeu L; Revilla-López E; Jarque M; Crespo E; Torija A; Bravo C; Los Arcos I; Meneghini M; Favà A; Román A; Monforte V; Bestard O
J Infect Dis; 2021 Aug; 224(3):526-531. PubMed ID: 33245359
[TBL] [Abstract][Full Text] [Related]
33. Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia.
Lisboa LF; Kumar D; Wilson LE; Humar A
Transplantation; 2012 Jan; 93(2):195-200. PubMed ID: 22179399
[TBL] [Abstract][Full Text] [Related]
34. Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study.
Chemaly RF; El Haddad L; Winston DJ; Rowley SD; Mulane KM; Chandrasekar P; Avery RK; Hari P; Peggs KS; Kumar D; Nath R; Ljungman P; Mossad SB; Dadwal SS; Blanchard T; Shah DP; Jiang Y; Ariza-Heredia E
Clin Infect Dis; 2020 Dec; 71(9):2365-2374. PubMed ID: 32076709
[TBL] [Abstract][Full Text] [Related]
35. Cytomegalovirus Immune reconstitution in cord blood transplant recipients on letermovir prophylaxis.
Abidi MZ; Molina KC; Garth K; Gutman JA; Weinberg A
Transpl Infect Dis; 2023 Oct; 25(5):e14104. PubMed ID: 37436771
[TBL] [Abstract][Full Text] [Related]
36. Monitoring of CMV-specific cell-mediated immunity with a commercial ELISA-based interferon-γ release assay in kidney transplant recipients treated with antithymocyte globulin.
Fernández-Ruiz M; Rodríguez-Goncer I; Parra P; Ruiz-Merlo T; Corbella L; López-Medrano F; Polanco N; González E; San Juan R; Folgueira MD; Andrés A; Aguado JM
Am J Transplant; 2020 Aug; 20(8):2070-2080. PubMed ID: 31991045
[TBL] [Abstract][Full Text] [Related]
37. Functional impairment of CMV-reactive cellular immunity during pregnancy.
Reuschel E; Barabas S; Zeman F; Bendfeldt H; Rascle A; Deml L; Seelbach-Goebel B
J Med Virol; 2017 Feb; 89(2):324-331. PubMed ID: 27447923
[TBL] [Abstract][Full Text] [Related]
38. Monitoring of Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity in Heart Transplant Recipients: Clinical Utility of the QuantiFERON-CMV Assay for Management of Posttransplant CMV Infection.
Chiereghin A; Potena L; Borgese L; Gibertoni D; Squarzoni D; Turello G; Petrisli E; Piccirilli G; Gabrielli L; Grigioni F; Lazzarotto T
J Clin Microbiol; 2018 Apr; 56(4):. PubMed ID: 29305542
[TBL] [Abstract][Full Text] [Related]
39. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
[TBL] [Abstract][Full Text] [Related]
40. Viral load, CMV-specific T-cell immune response and cytomegalovirus disease in solid organ transplant recipients at higher risk for cytomegalovirus infection during preemptive therapy.
Martín-Gandul C; Pérez-Romero P; Blanco-Lobo P; Benmarzouk-Hidalgo OJ; Sánchez M; Gentil MA; Bernal C; Sobrino JM; Rodríguez-Hernández MJ; Cordero E;
Transpl Int; 2014 Oct; 27(10):1060-8. PubMed ID: 24964364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
